Last reviewed · How we verify
NCT02985307: SMS
Impact of Mobile Phone Texting Service to Support Weight Loss
NA trial testing Short Message Text Service in Obesity in 120 participants. Completed in 30 November 2018.
30 November 2018
Quick facts
| Lead sponsor | NHS Lothian |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 120 |
| Start date | 28 April 2017 |
| Primary completion | 30 November 2018 |
| Estimated completion | 30 November 2018 |
| Sites | 2 locations across United Kingdom |
Drugs / interventions tested
- Short Message Text Service
- Standard Weight Management Group
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
NHS Lothian — full company profile →
Who can join
18 and older, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the efficacy of a mobile telehealth short message service as a facilitator for weight management. Half of the participants will receive a standard care weight management group intervention, while the other half will receive daily text messages via their mobile phone to help facilitate weight loss. It is hypothesized that the intervention group receiving text messages will be as successful as the control group at achieving weight loss over a 3-month period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02985307
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other NHS Lothian trials
Trials by the same sponsor.
- NCT06117059 — The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance · NA · recruiting
- NCT05290818 — Total Versus Robotic Assisted Unicompartmental Knee Replacement · NA · recruiting
- NCT06932978 — The Use of Smart Glasses for Environmental Controls · NA · completed
- NCT06212622 — Is the Rate of Early Mobilisation in Hip Fracture Patients Using Alfentanil Better Than Standard Opioid Analgesia? · completed
- NCT07049419 — The Impact of Environmental Controls on Mental Health · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02985307 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NHS Lothian
- Last refreshed: 3 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02985307.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing